Ultrasound Shown to be Superior Diagnostic Compared to Mammography in Women Ages 30-39
Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial
New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years
Two Phase II Trials Display Ramucirumab Potential Efficacy
Gene Variant Associated With 44 Percent Cancer Risk Reduction
Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant
HCT Survivors More Likely To Show Heart Disease Risk Factors
PV-10 Produces 51 Percent Response Rate in Phase II Trial
Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk
Three Studies Test Oncotype DX In Breast and Colon Cancers
NCI-Approved CTEP Trials For the Month of October
FDA Approves Abraxane And Alimta for NSCLC
Trending Stories
- Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - ACOG says it will no longer accept federal funding
- Andrea Werblin Reid’s unflinching poetry documents the realities of cancer care, clinical trials, and loss
Her collection, “To See Yourself As You Vanish,” will be published three years after her death - U.S. News & World Report expands evaluation of outcomes in cancer subspecialties